2 results
Approved WMOCompleted
Primary Study ObjectiveTo assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via registered intramuscular (IM) injection…
Approved WMOCompleted
Investigate whether different resection modalities such as MO or TL cause a different amount of shrinkage in the mucosal margins of resected OSCCs.